Comparison of Culture and Molecular Identification of Bacteria in Chronic Wounds by Rhoads, Daniel D. et al.
Int. J. Mol. Sci. 2012, 13, 2535-2550; doi:10.3390/ijms13032535 
 
International Journal of 
Molecular Sciences 
ISSN 1422-0067 
www.mdpi.com/journal/ijms 
Article 
Comparison of Culture and Molecular Identification of Bacteria 
in Chronic Wounds 
Daniel D. Rhoads 
1,2, Randall D. Wolcott 
1,3,4,*, Yan Sun 
3 and Scot E. Dowd 
3,4 
1  Southwest Regional Wound Care Center, Lubbock, TX 79410, USA 
2  Texas Tech University Health Sciences Center School of Medicine, Lubbock, TX 79415, USA 
3  Research and Testing Laboratory, Lubbock, TX 79407, USA 
4  Pathogenius Laboratory, Lubbock, TX 79407, USA 
*  Author to whom correspondence should be addressed; E-Mail: randy@randallwolcott.com;  
Tel.: +1-806-793-8869. 
Received: 1 November 2011; in revised form: 30 January 2012 / Accepted: 13 February 2012 /  
Published: 23 February 2012 
 
Abstract: Clinical diagnostics of chronic polymicrobial infections, such as those found in 
chronic wounds, represent a diagnostic challenge for both culture and molecular methods. 
In the current retrospective study, the results of aerobic bacterial cultures and culture-free 
bacterial identification using DNA analyses were compared. A total of 168 chronic wounds 
were studied. The majority of bacteria identified with culture testing were also identified 
with molecular testing, but the majority of bacteria identified with the molecular testing  
were not identified with culture testing. Seventeen (17) different bacterial taxa were 
identified with culture, and 338 different bacterial taxa were identified with molecular testing. 
This study demonstrates the increased sensitivity that molecular microbial identification can 
have over culture methodologies, and previous studies suggest that molecular bacterial 
identification can improve the clinical outcomes of patients with chronic wounds. 
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1. Introduction  
1.1. Chronic Wounds 
Chronic wounds, wounds that fail to progress through normal wound healing trajectory, are a large 
and growing problem for an already burdened healthcare system. The major chronic wounds (diabetic 
foot ulcers, venous leg ulcers, pressure sores, nonhealing surgical wounds) are all increasing at alarming 
rates due to sedentary lifestyles, obesity and, most importantly, double digit increases in diabetes each 
year. The total cost of chronic wounds is difficult to measure but has been estimated in over 25 billion 
dollars a year, but even more importantly is the patient impact resulting in loss of limb and eventually 
loss of life for far too many patients [1,2]. 
Wound care providers treat wounds as if the bioburden is one of the major barriers to wound healing. 
Debridement, antibiotics, and topical antiseptics are routinely used in managing the microbes that are 
universally found on chronic wounds. Yet, the only microbial diagnostic tool available to wound care 
providers until recently has been the routine clinical culture. The role of bacteria in chronic wounds and 
the appropriateness of using antimicrobial agents in the routine management of chronic wounds is   
a source of continual debate in the wound care community [3–5]. It is reasonable to consider that 
improving the methods of microbial detection and identification may be more successful in helping the 
clinician deal with this important healthcare problem. 
1.2. Bacterial Biofilms 
It is now recognized that the overwhelming majority of bacteria in their natural habit exist in a   
biofilm phenotype [6]. Chronic biofilm infections affect every organ system, including the integumentary 
system [7–9]. Bacterial biofilms in chronic wounds affect millions in the United States each year [1].  
Biofilms are inherently different from the bacterial clones that are cultivated in laboratories. In order 
to standardize testing of bacteria, the convention has been to examine free-floating clonal populations  
of a single species during its logarithmic growth phase. Unfortunately, biofilms are archetypically 
surface-associated groups, often comprised of multiple genera or kingdoms of organisms, held together 
by an extracellular matrix; and the growth conditions and population within the biofilm can be 
spatially and temporally variable [10]. By definition, biofilms are more resistant to antimicrobial 
agents than the planktonic cells cultivated in the laboratory, and the level of resistance can be two or 
three orders of magnitude greater for cells within a biofilm [11]. Biofilms are also resistant to host 
immunity defenses [8]. Unfortunately, the patients who develop chronic wounds are often immune 
compromised in some way (e.g., poor circulation or hyperglycemia), which facilitates the establishment 
of bacterial biofilm communities and makes elimination of the biofilm all the more difficult. 
Multiple bacteria genera comprise the biofilm in chronic wounds [9,12,13], and some of these 
bacterial taxa seem to commonly co-occur with each other [12,14]. In oral biofilm disease, co-occurrence 
of bacterial taxa has been well described spatially and temporally, and its relevance to the biofilm’s 
pathogenesis has been described [10]. This description has not yet been established in chronic wounds, 
but it has caused some to question the traditional paradigm of infection. The lack of a single identifiable 
bacterial species causing an infection in chronic wounds has caused some to question the relevance of 
Koch’s postulates as it pertains to chronic wound infections [15]. It has been proposed that the cause of Int. J. Mol. Sci. 2012, 13 2537 
 
chronic wound infections may not be able to be reduced to a single species of bacteria, but perhaps the 
collective polymicrobial biofilm community may be required for effective chronic pathogenesis by the 
bacteria [15–17]. 
1.3. Bacteria in Wounds 
The debate over which organisms are harmless, helpful, or hateful to humans is continually being 
investigated and debated. A prerequisite assumption to this debate is that the presence of bacteria in or 
on humans is accurately being detected and identified. Traditionally, the presence of bacteria in or on 
humans during health or disease has been determined by growing the bacteria in culture. Indeed, Koch’s 
postulates and infectious disease dogma are anchored in culture technology. However, molecular biology 
has proven that culture methodologies can be markedly less sensitive to bacterial detection than DNA 
detection methodologies [13]. Also, the identification of bacteria is shifting away from the traditional 
metabolic biochemical testing of cultures and moving towards genetic or proteomic identification of 
the bacteria [13,18,19]. The advent of molecular microbiology has caused medicine to reexamine 
Koch’s postulates [20,21]. Also, science’s growing understanding of biofilms’ role in disease, has led 
others to challenge the relevance of Koch’s postulates in biofilm wound infections [15]. Some have 
recognized that infections can be caused by bacteria that are not especially virulent but which 
commonly comprise part of the benign or symbiotic human microbiome. However, these normally 
benign organisms are capable of filling the niche provided to them by an impaired host, thereby 
causing disease and being implicated as a pathogen [20]. Others suggest that it may not be a single 
species that causes chronic wound infections, but the collective biofilm can assert a pathogenicity that 
the component parts are less capable of exerting [15–17]. 
1.4. Molecular Identification of Bacteria 
Molecular technologies have enabled investigators to examine human microbiota more deeply and 
sensitively than culture testing has allowed [16,17]. In our experience, these molecular tests can reveal 
an order of magnitude greater number of bacterial species in chronic wounds than culture results 
demonstrate. We have used molecular microbial diagnostic information to develop personalized 
medicine methods in wound care, which has improved patient outcomes [22,23].  
It is encouraging that these new molecular microbial diagnostic tests are enabling improvement in 
patient care, but it is also necessary to continue to formally compare these newer methods with traditional 
culture methods. Examining culture and molecular results in parallel is necessary in order to compare 
and contrast the methods’ abilities to detect bacteria in humans and to continue to evaluate the clinical 
relevance of molecular testing’s increased sensitivity. This study is an early attempt to compare clinical 
laboratory results of parallel testing of aerobic cultures and culture-free bacterial identification using 
16S rDNA sequencing. Int. J. Mol. Sci. 2012, 13 2538 
 
2. Study Design and Methods 
This study was performed retrospectively on subjects who had undergone parallel bacterial analysis 
of wound samples. Initially, the results obtained by the Bacterial Identification Methods (2.3) were used 
clinically to guide patient care. 
2.1. Inclusion Criteria 
Subjects were included in the study if they met the following criteria:  
(1) The presence of a chronic wound (“Chronic wound” is defined as a wound that fails to progress 
through the normal healing trajectory); 
(2) Debridement required as part of standard of care wound management; 
(3) The medical record revealed that parallel samples from the wound were sent for both, culture 
and molecular testing. 
2.2. Sample Collection 
Samples were collected from 168 subjects’ chronic wounds at the Southwest Regional Wound   
Care Center (Lubbock, Texas, USA) in accordance with Western Institutional Review Board protocol 
number 20062347. 
2.3. Bacterial Identification Methods 
2.3.1. Culture Identification of Bacteria 
Samples were tested using routine aerobic culture techniques in a non-hospital CLIA certified 
laboratory in Lubbock, Texas, USA. 
2.3.2. Molecular Identification of Bacteria using 16S Sequencing 
Samples were prepared and analyzed by PathoGenius Laboratory (Lubbock, Texas, USA), a College 
of American Pathologists accredited laboratory. 
2.3.2.1. DNA Extraction 
The debridement samples were centrifuged and then suspended in 500 μL RLT buffer (Qiagen, 
Valencia, CA) (with b-mercaptoethanol). A sterile 5 mm steel bead (Qiagen, Valencia, CA) and 500 μL 
sterile 0.1 mm glass beads (Scientific Industries, Inc., NY, USA) were added for complete bacterial lysis 
in a Qiagen TissueLyser (Qiagen, Valencia, CA), run at 30 Hz for 5 min. Samples were centrifuged 
briefly and 100 μL of 100% ethanol added to a 100 μL aliquot of the sample supernatant. This mixture 
was added to a DNA spin column, and DNA recovery protocols were followed as instructed in the 
QIAamp DNA Mini Kit (Qiagen, Valencia, CA) starting at step 5 of the Tissue Protocol. DNA was 
eluted from the column with 30 μL water and samples were diluted accordingly to a final concentration 
of 20 ng/μL. Int. J. Mol. Sci. 2012, 13 2539 
 
2.3.2.2. Partial Ribosomal Amplification  
The modified 16S Eubacterial primers 28F, 5′-GAG TTT GAT CNT GGC TCA G-3′ and 519R,  
5′-GTN TTA CNG CGG CKG CTG-3′ were used for amplifying the 500 bp region of 16S rRNA genes. 
The primer sets used for FLX-Titanium amplicon pyrosequencing were designed with adding linker A 
and 8 base pair subject-specific barcode sequence at the 5′ end of forward primers as follow: 28F-A,  
5′-CCA TCT CAT CCC TGC GTG TCT CCG ACT CAG-barcode-GAG TTT GAT CNT GGC TCA 
G-3′. The biotin and linker B sequence at the 5′ end of reverse primer 519R-B: 5′-Biotin-CCT ATC 
CCC TGT GTG CCT TGG CAG TCT CAG GTN TTA CNG CGG CKG CTG-3′. HotStarTaq Plus 
Master Mix Kit (QIAGEN, CA, USA) was used for PCR under the following conditions: 95 °C for  
5 min followed by 35 cycles of 95 °C for 30 s; 54 °C for 40 s and 72 °C for 1 min, a final elongation 
step at 72 °C for 10 min was also included. The PCR products were cleaned by using Diffinity Rapid 
Tip (Diffinity Genomics, Inc, West Henrietta, NY) and pooled. The small fragments were removed by 
Agencourt Ampure Beads (Beckman Coulter, CA, USA).  
2.3.2.3. Massively Parallel bTEFAP Titanium 
Bacterial tag-encoded FLX-Titanium amplicon pyrosequencing (bTEFAP) was performed as 
described previously [17]. In preparation for FLX-Titanium sequencing (Roche, Nutley, New Jersey), 
a sample of double-stranded DNA was combined with DNA capture beads, and amplified by emulsion 
PCR. After bead recovery and bead enrichment, the bead attached DNAs were denatured with NaOH, 
and sequencing primers (Roche) were annealed. A 454 sequencing run was performed on a GS 
PicoTiterPlate (PTP) using the Genome Sequencer FLX System (Roche). All FLX procedures were 
performed using Genome Sequencer FLX System manufacturer’s instructions (Roche). 
2.3.3. Polymerase Chain Reaction  
The diagnostic panel for quantitative real-time PCR consists of Pseudomonas aeruginosa, Group B 
Streptococcus agalactiae (Group B Streptococcus), Streptococcus pyogenes (Group A Streptococcus), 
Staphylococcus aureus, Klebsiella pneumonia, Serratia marcescens, Candida albicans, Enterococcus 
faecalis, Enterococcus faecium. The enterococci were reported collectively in this paper as “Group D 
Enterococcus”. The quantitative real-time PCR was performed by a Roche Light Cycler 480 as described 
previously [24]. The PCR reactions were as follows: deactivation, 95 °C for 10 s; amplification,   
35 cycles of 95 °C for 15 s, 60 °C for 1 min.  
2.4. Description of Analysis 
The concordance or discordance of molecular results with culture results were identified as 
“concordant”, “discordant”, or “partially concordant”. “Concordance” was defined as detecting the same 
bacterium/bacteria using molecular testing as were detected using culture testing. “Discordance” was 
defined as not detecting the bacterium/bacteria using molecular testing when the bacterium/bacteria   
was identified using culture testing. “Partial concordance” was possible when multiple bacteria were 
identified by culture. In partially concordant subjects’ samples, one or more of the bacteria identified by Int. J. Mol. Sci. 2012, 13 2540 
 
culture were also identified by molecular testing and one or more of the bacteria identified by culture 
were not identified by molecular testing. 
3. Results of Bacterial Identification  
One hundred sixty-eight (168) wounds from 168 subjects were analyzed by both culture and 
molecular testing including 24 decubitus ulcers, 40 diabetic extremity wounds, 23 non-healing surgical 
sites, 49 venous leg ulcers, and 32 wounds from trauma or an abscess. The most common results using 
both culture and molecular testing are reported by wound type in Table 1. Overall, when considering 
all 168 wounds, the most common organism identified using both culture and molecular testing was 
Staphylococcus aureus. In total, 17 different bacterial taxa were identified by culture. These organisms, 
the frequency of culture of each organism, and the corresponding frequency of detection by molecular 
testing are reported in Table 2. When considering all 168 wounds, 338 different bacterial taxa were 
identified by molecular testing. Of the 338 bacterial taxa, the 20 most frequently identified taxa and  
the frequency of their detection are reported in Table 3. The majority of the taxa were detected to  
be less than 1% of the total microbiota in any given wound. Briefly, culture commonly identified 
Staphylococcus, Enterococcus, Serratia, and Pseudomonas. Molecular testing commonly identified 
Staphylococcus, Finegoldia, Corynebacterium, Anaerococcus, Bacteroides, and Serratia. 
Table 1. An overview of wound types and most results for each wound type are listed. The 
most common results are at the top. Only the top 5 most common results for each wound 
type is presented. The number of wounds (# wounds) in each category is provided. 
Anaerobes are indicated (*), and anaerobes were not attempted to be detected by culture. 
Type of wound  # wounds  Culture overview   Molecular overview 
Decubitus ulcer  24  Enterococcus 
Staphylococcus 
Pseudomonas 
Serratia 
Proteus 
Corynebacterium 
Peptoniphilus * 
Staphylococcus 
Anaerococcus * 
Bacteroides * 
Diabetic extremity ulcer  40  Enterococcus 
Pseudomonas 
Streptococcus 
Serratia 
Staphylococcus 
Anaerococcus * 
Peptoniphilus * 
Corynebacterium 
Finegoldia * 
Pseudomonas 
Surgical site  23  Staphylococcus 
Serratia 
Enterococcus 
no growth 
Pseudomonas 
Corynebacterium 
Staphylococcus 
Bacteroides * 
Prevotella 
Serratia 
Venous leg ulcers  49  Staphylococcus 
no growth 
Serratia 
Streptococcus 
Pseudomonas 
Corynebacterium 
Staphylococcus 
Bacteroides * 
Prevotella 
Peptoniphilus * Int. J. Mol. Sci. 2012, 13 2541 
 
Table 1. Cont. 
Type of wound  # wounds  Culture overview   Molecular overview 
Trauma/abscesses 32  no growth  
Staphylococcus 
Enterococcus 
Serratia 
Pseudomonas 
Staphylococcus 
Prevotella 
Bacteroides * 
Peptoniphilus * 
Corynebacterium 
Table 2. The 17 bacterial taxa identified in 168 chronic wound samples using aerobic 
culture testing are listed. The number of wounds which were culture positive for each taxa 
are listed in the second column. The number of wounds which were positive for each taxa 
using 16S rDNA testing are listed in the third column. 
Bacterial taxa detected from 168 
samples using aerobic culture testing 
Number of 
positive samples 
using culture 
Number of positive 
samples using 16S 
sequencing 
Staphylococcus aureus  41 72 
Enterococcus spp.  35  28 
Serratia marcescens  35 39 
Pseudomonas  24 27 
Staphylococcus spp. (not S. aureus) 20  47 
Streptococcus agalactiae  18 23 
Proteus mirabilis  9 10 
Citrobacter freundii  5 6 
Escherichia coli  4 3 
Klebsiella pneumoniae  3 8 
Enterobacter aerogenes  2 3 
Enterobacter cloacae  2 3 
Morganella morganii  2 5 
Streptococcus spp.  2 41 
Xanthomonas maltophilia 2  3 
Acinetobacter baumannii  1 5 
Providencia spp.  1 2 
Table 3. The 20 most frequently detected bacteria in chronic wounds using DNA testing. 
Legend: 
1 indicates bacteria in the top 20 bacteria identified by DNA testing which were 
also in the list of bacteria identified using culture methods; 
2 indicates anaerobic bacteria, 
which were not attempted to be cultured. 
Bacteria identified using comprehensive molecular diagnostics # of chronic wounds
Staphylococcus aureus 
1 72 
Finegoldia magna 
2 54 
Corynebacterium striatum  53 
Anaerococcus vaginalis 
2 39 
Bacteroides vulgatus 
2 39 
Serratia marcescens 
1 39 
Prevotella sp.  34 Int. J. Mol. Sci. 2012, 13 2542 
 
Table 3. Cont. 
Bacteria identified using comprehensive molecular diagnostics # of chronic wounds
Peptoniphilus harei 
2 33 
Peptoniphilus ivorii 
2 30 
Pseudomonas sp. 
1 27 
Anaerococcus sp. 
2 26 
Streptococcus agalactiae. 
1 23 
Klebsiella sp.  18 
Prevotella sp.  17 
Enterococcus sp. 
1 15 
Peptoniphilus sp. 
2 15 
Corynebacterium tuberculostearicum 14 
Peptostreptococcus sp. 
2 14 
Clostridium cellobioparum 
2 12 
Staphylococcus capitis 11 
Table 4. Results for 10 representative samples are reported. In addition to bacterial culture 
and 16S sequencing, PCR testing for bacteria and yeast, 18S sequencing for yeast, and 
identification of yeast during bacterial culture are also included in this table. The PCR 
testing examined each sample for Candida albicans,  Group D Enterococcus, Klebsiella 
pneumoniae, Pseudomonas aeruginosa,  Staphylococcus  aureus,  Streptococcus agalactiae, 
and Streptococcus pyogenes. The 16S /18S sequencing reports the presence of the organisms 
with a corresponding percentage. The percentage indicates the amount which the organism 
contributed to the whole of the microbiota, which was detected in the sample.  
Sample Culture  PCR  16S  &  18S  % Comments 
1  Pseudomonas 
aeruginosa 
Pseudomonas 
aeruginosa 
Pseudomonas 
aeruginosa 
65 Good agreement between all 3 testing 
methods 
     Finegoldia magna *  30
     Group  D  Enterococcus <1
     Serratia marcescens  <1
2  Streptococcus 
spp. 
Streptococcus 
pyogenes 
Prevotella *  49 Streptococci were detected by culture, 
but staphylococci were missed by 
culture. The molecular methods are in 
agreement, but the predominant 
bacterium in the sample was not 
attempted to be detected by culture or 
PCR. 
   Streptococcus 
agalactiae 
Staphylococcus aureus  21
   Staphylococcus 
aureus 
Unknown Bacterium  16
     Streptococcus 
agalactiae 
9
     Streptococcus pyogenes  4
3 No  Growth  Klebsiella 
pneumoniae 
Haemophilus 
parainfluenza 
33 The predominant bacterium was 
missed by culture and not attempted 
to be detected by PCR. Yeast and 
bacteria were both detected by 
molecular methods. 
   Candida 
albicans 
Candida albicans  15
     Klebsiella pneumoniae  13
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Table 4. Cont. 
4  Pseudomonas spp. Streptococcus 
pyogenes 
Serratia spp.  31 Culture and PCR detected two different 
organisms. 16S sequencing detected both 
organisms, but several other bacteria were 
present at a higher concentration in the 
sample than either of the bacteria detected 
by culture or PCR. 
     Peptoniphilus harei *  28
     Corynebacterium 
striatum 
9 
     Pseudomonas spp.  5 
     Streptococcus 
pyogenes 
<1
5  Serratia 
marcescens 
Serratia 
marcescens 
Corynebacterium 
striatum 
50 Serratia was detected by all methods, but 
16S determined it to be a small contributor 
to the microbiota.     Proteus mirabilis    Anaerococcus 
vaginalis * 
19
     Serratia marcescens  3 
     Proteus spp.  2 
6  Staphylococcus 
aureus 
Staphylococcu
s aureus 
Prevotella spp. *  40 Staphylococcus was detected by all 
methods, but 16S determined it to be a 
very small contributor to the microbiota. 
The most predominant organisms were 
anaerobes that were not attempted to be 
detected by culture or PCR. 
     Unknown  Bacterium 32
     Bacteroides vulgatus 
* 
25
     Staphylococcus 
aureus 
<1
7  Acinetobacter 
baumannii 
Group D 
Enterococcus 
Staphylococcus spp.  83 Culture and PCR detected different organisms, 
and 16S sequencing confirmed the presence of 
all of these organisms. PCR detected bacteria 
that were very small contribultors to the 
microbiota.  
   Streptococcus 
pyogenes 
Acinetobacter 
baumannii 
6 
     Streptococcus pyogenes  <1
     Group D Enterococcus  <1
8  No Growth  Negative  Unknown Bacterium  91 The predominant bacterium is from an unknown 
bacterium 
9  Klebsiella 
pneumoniae 
Klebsiella 
pneumoniae 
Klebsiella pneumoniae  43 All methods agree that Klebsiella and 
Enterococcus are present in the sample. PCR 
detected Staphylococcus, which 16S sequencing 
determined to be a very small contributor to the 
microbiota. 
  Enterococcus spp.  Group D 
Enterococcus 
Unknown Bacterium  23
   Staphylococcus 
aureus 
Group D Enterococcus  16
     Veillonella spp. *  16
     Staphylococcus aureus  <1
10  Yeast  Candida albicans  Candida albicans  63 All methods detected yeast. Molecular methods 
also detected Staphylococcus.     Staphylococcus 
aureus 
Staphylococcus aureus  12
GREEN: Organism detected with all three testing methods; RED: Organism detected with two only 
two testing methods; *: Bacterium is an obligate anaerobe. No obligate anaerobes were attempted 
to be detected by culture or PCR. 
A subset of results are reported more exhaustively in Table 4. The table compares the results of  
10 samples as determined by culture and 16S sequencing. Additionally, the results from PCR assays, Int. J. Mol. Sci. 2012, 13 2544 
 
18S sequencing detection of yeast, and incidental identification of yeast during bacterial culture are 
included in the table. Different taxa were determined to be major contributors to the microbiota in 
different wounds. Some sample results were very similar across testing methods, and other samples 
revealed a large amount of variability from method to method. Overall, the table demonstrates that 
deep 16S/18S sequencing detects organisms that are detected using other molecular methods (PCR) 
and culturing methods. 
From the culture-based diagnostics, a total of 11 (7%) chronic wounds were found to have 3 different 
bacterial taxa, 40 of the samples (24%) had 2 bacterial taxa, and 95 of the wounds (57%) had a single 
bacterium cultured. 22 of the wounds (13%) were found to have no culturable bacteria. Seventeen (17) 
different bacterial taxa were identified using culture based methods (Table 2).  
Molecular testing identified 338 different bacterial taxa (mean of 6.9 different bacterial taxa per 
wound with a range of 1–33) in the 168 wounds. None of the chronic wounds were reported as 
negative based upon molecular diagnostics. It is of note that out of the top 20 most ubiquitous bacteria 
identified with molecular methods, 9 of these taxa are anaerobes (Table 3). Anaerobic cultures were 
not performed. 
Of the 168 paired samples, 131 of the samples (78%) demonstrated some level of concordance 
between culture and molecular results. In 105 of the samples (63%), the molecular results   
were concordant with the culture results. Twenty-six (26) samples (15%) had partial concordance. 
Fifteen (15) samples (9%) were discordant. Twenty-two (22) samples (13%) were negative by   
culture testing but positive with molecular testing. In these 22 samples, molecular testing   
revealed these bacteria: Bacteroidetes (unknown genus), Bacteroides,  Finegoldia,  Peptoniphilus, 
Anaerococcus,  Propionibacterium,  Ruminococcus,  Prevotella,  Eubacterium,  Streptococcus, 
Corynebacterium, Arthrobacter, Acinetobacter, Paracoccus, and Micrococcus. Many of these genera 
are obligate anaerobes. 
Of the 105 samples with complete concordance, 55 samples were in agreement between culture and 
molecular testing as to which bacteria were most prevalent in the sample. In 15 of the 105 samples, 
culture and molecular testing were not in agreement as to which bacteria were most prevalent in   
the sample, but the cultured organism(s) was determined to be one of the 3 most prevalent organisms 
by using molecular testing. In the other 35 samples, the cultured bacteria were identified as 
representing a minor population (not one of the 3 most prevalent bacteria within the sample) when 
using molecular methods.  
Of the 41 samples with partial concordance or complete discordance, the bacteria that were cultured 
but not detected by molecular testing are were as follows: Enterococcus spp. (19 times), Staphylococcus 
spp. (6 times), Pseudomonas spp. (4 times), Serratia marcescens (3 times), Enterobacter (3 times), 
Citrobacter (3 times), Proteus (1 time), Xanthamonas (1 time), and Klebsiella (1 time). Thirty-two (32) 
of these 41 samples were determined by molecular methods to have strong anaerobic contribution to the 
microbiota (primarily Bacteroides, Peptoniphilus, Finegoldia, Anaerococcus, and Clostridium).  
More exhaustive results of a subset of 10 samples are reported in Table 4 to demonstrate the clinical 
relevance of the two methods. The culture results and 16S sequencing results are reported. In addition 
to these results, incidental findings of yeast by culture, results from PCR assays for select organisms, 
and results of 18S sequencing for yeast [25] are reported. Not all of the organisms detected using 
16S/18S sequencing are reported. Results are reported for those organisms that met at least one of the Int. J. Mol. Sci. 2012, 13 2545 
 
following criteria: (1) contributed to 10% or more of the microbiota in the sample; (2) were attempted 
to be detected using PCR or (3) were identified by culture. The lower sensitivity of bacterial culturing is 
demonstrated in this table. A PCR-targeted species was detected in six samples by both PCR and 16S 
sequencing (Samples 2, 3, 4, 7, 9, 10) but was not detected by culture. Cultures were able to detect 
bacteria for which PCR detection was not attempted (Sample 5 & 7). This demonstrates the broad 
sensitivity of cultures when compared to PCR testing. PCR testing is highly sensitive but requires the 
laboratory to specifically test for each bacterium of interest with an individualized assay. 16S/18S 
sequencing has both broad sensitivity (similar to culturing) and high sensitivity (similar to PCR). 
Molecular methods (PCR and 16S/18S sequencing) are sensitive and specific. PCR’s specificity is 
demonstrated by the results of Sample 4. Sample 4 was negative for P. aeruginosa, but another 
pseudomonad species was detected by both culture and 16S sequencing. The only discrepancy between 
16S sequencing and PCR is in Sample 1, in which S. marcescens and Group D Enterococcus were 
detected by 16S sequencing and not detected by PCR. This contradiction in results is likely due to the 
high sensitivity of deep 16S sequencing and not due to poor specificity of 16S sequencing. Congruent 
with that explanation, 16S sequencing detected that S. marcescens and Group D Enterococcus 
comprised a very small portion of the total microbiota in Sample 1. Overall, the table demonstrates that 
deep 16S/18S sequencing detects organisms that are detected using other molecular methods (PCR) 
and culturing methods. 
4. Analysis and Discussion of Results 
Culture results and 16S DNA sequencing results were compared more exhaustively in a subset of 
samples (Table 4). Quantitative PCR results were also reported, which help to clarify discrepancies in 
the results between culturing and 16S sequencing. PCR also helped to verify the results of cultures and 
16S sequencing. The results of the additional PCR testing demonstrate close correlation between the 
molecular results: PCR and 16S sequencing. Culture results appear to be less sensitive than the 
molecular testing methods, as has been well established. PCR testing results are similar to the 16S 
sequencing results. However, 16S sequencing has the potential to detect almost any clinically relevant 
bacterium, even bacteria that are not yet well described. For example, Samples 2, 8, and 9 were 
determined to have a significant portion of unknown bacteria in the wound microbiota. In contrast, 
PCR assays need to be designed to investigate each bacterium of interest. The rapidity of PCR testing 
is a potential advantage over both culturing and 16S sequencing. However, the advent of MALDI-TOF 
identification of bacterial cultures is likely to significantly decrease the turn around time for culture 
results. Still, cultures will continue to take greater than 24 h, but some molecular tests can potentially be 
complete within one working day. The turn around time for molecular testing is likely to continue to 
decrease as molecular technologies and computational hardware improve. Molecular methods maintain 
an advantage, at least theoretically, in turn around time; and molecular methods are more sensitive 
than cultures. 
In the present study, the microbes that were both commonly predominant in wounds according to 
molecular testing and also not identified using culture methods were often bacteria that were obligate 
anaerobes. The results support the interpretation that aerobic cultures alone (as in this study) fail to 
resolve the complexity of the polymicrobial nature of chronic wounds. Although anaerobes were not Int. J. Mol. Sci. 2012, 13 2546 
 
attempted to be cultured, it is reasonable to estimate that the frequency with which anaerobes would 
have been detected would have been similar to the frequency with which aerobes were detected. As 
reported previously, although anaerobes are difficult to culture, they often comprise a large portion of 
the microbiota of chronic wounds [13,16]. The detection of aerobes by culture was largely in agreement 
with the molecular results, but molecular testing often found many more bacteria and bacteria that were 
larger contributors to the microbiota than those detected by culture. Molecular diagnostics are able   
to resolve a more accurate and actionable diagnosis [22,23,26]. This study contributes to a large body  
of evidence that recognizes the existence of anaerobes as an important population in chronic wound 
biofilms [13,16,27,28]. Evidence is also abundant in the scientific literature that chronic wounds are 
highly polymicrobial infections, which supports the findings made with the molecular methods used in 
this study [12,23,29,30].  
Bowler and Davies conducted one of the most comprehensive culture-based surveys of chronic 
wounds with methods specifically designed to enrich for and detect anaerobes, which revealed that 
anaerobes were highly prevalent [16,31]. In this study, the 41 samples showing discordance or partial 
concordance between culture and molecular testing commonly had large anaerobic bacterial populations 
as determined using molecular testing. The 16S DNA from these anaerobes may have diluted the 
concentration of 16S DNA from the aerobes in the sample that went undetected. Aerobic organisms that 
were not detected by molecular testing may have been present below the level of sensitivity. If this is 
true, then these bacteria should be able to be detected in the future by sequencing a greater number of 
16S rDNA molecules from the samples, thereby increasing the test’s sensitivity. Another potential 
cause of decreased sensitivity using 16S rDNA interrogation is the potentially large portion of the 
extracted DNA that is human and not bacterial in origin [13]. It is also important to note, if anaerobes 
are inadequately investigated within a wound (such as with aerobic-only cultures as in this study), 
clinicians could incorrectly infer that minor contributors to the bacterial population (cultured aerobic 
bacteria) comprise a substantial portion of the wound microbiota (e.g., Table 4, Samples 2 and 6). This 
could result in targeting the “wrong” bacteria for antimicrobial therapy. It is clinically important to 
investigate the presence of anaerobes in chronic wounds. 
Molecular testing identified each taxon more frequently than culturing with the exception of 
Enterococcus and Escherichia coli (Table 2). Enterococci were cultured from 35 samples but only  
28 samples were positive using molecular testing. We have found similar results in another study 
(pending publication) and can identify several possible reasons for this finding: potentially higher 
sensitivity of the culture method beyond the sensitivity of the molecular method, misidentification of 
the bacterium by culture or by molecular testing, or contamination of the sample. 
There were 22 culture-negative/molecular-positive samples and no culture-positive/molecular-
negative samples. These findings could be a result of several differences in the testing methodologies. 
Either culturing produces false negative results (poor sensitivity) or molecular testing produces false 
positive results (poor specificity). Or, some combination of the two proposed explanations is possible. 
The verification of 16S sequencing results by PCR testing (Table 4) helps to rule out the cause of the 
discrepancies being linked to false positive results using 16S analysis. The sensitivity of culturing can 
be lowered by the presence of viable but not culturable (VBNC) bacteria, including the VBNC 
persister bacteria within biofilms [32]. While the potential bias exists for the detection of nonviable 
bacteria with molecular methods, it has been reported that nucleic acid artifact from dead bacteria do Int. J. Mol. Sci. 2012, 13 2547 
 
not reside for long periods of time in an active host environment [33,34]. Published studies suggest 
that using molecular bacterial detection results has the potential to improve clinical outcomes of 
patients with chronic infections more than the use of culture results [22,23,26]. 
A potential limitation of molecular diagnostics is the inability to test for phenotypic antibiotic 
sensitivity. It is important to consider the method in which phenotypic antibiotic testing is performed. 
Culture sensitivities are performed using planktonic phenotype bacteria and not biofilm phenotype 
bacteria. Obtaining the phenotypic sensitivity of biofilms is much more cumbersome than traditional 
susceptibility testing [35–37]. Biofilm bacteria are present in chronic wounds, and the resistance of  
this biofilm phenotype to antimicrobial agents can be orders of magnitude greater than the traditional 
laboratory culture methods can demonstrate [38–40]. Although not reported in this study, molecular 
methods are used in clinical laboratories to detect notable antibiotic resistance genes such as methicillin 
resistance and vancomycin resistance. The inability to determine planktonic antibiotic susceptibility 
remains a limitation for molecular methods, and the inability to determine the sensitivity of biofilm 
bacteria is a limitation for both culture and molecular testing. However, the genetic component of 
antibiotic resistance is able to be determined using molecular testing [41]. 
Molecular diagnostics have proven useful at the Southwest Regional Wound Care Center in   
the past [22,23]. Published retrospective studies compared the outcomes of chronic wound patients 
using culture-based diagnostics in which, over a 7 month period 48% of the wounds healed. In contrast, 
using molecular bacterial diagnostics (Pathogenius Laboratory, Lubbock, TX) and therapies that target 
the detected microbes, more than 90% of wounds healed within a similar 7 month period. In another 
recent study to compare culture and molecular methods, it was shown that only comprehensive 
molecular methods could be correlated with clinical outcomes [26]. The weight of evidence is growing 
that suggests comprehensive molecular bacterial diagnostic methods can better serve chronic wound 
patients than culture testing.  
5. Conclusions 
Here we evaluated 168 wounds with cultures and molecular diagnostics. Out of the 168 wounds a 
total of 17 different bacteria were cultured. Molecular methods identified 338 different bacterial taxa. 
The majority of these were detected in relatively low abundance (~1% of the wound microbiota). Culture 
identified up to 3 different bacteria in some wounds, and molecular testing identified individual wounds 
with up to 33 different bacteria. The majority of bacteria identified with culture were also identified with 
molecular testing, but the vast majority of bacteria identified with molecular methods were not identified 
with culture methods. Although not tested for by culture, anaerobes were commonly found to be a large 
component of the microbial population in these chronic wounds, which is consistent with previous 
studies. In several instances, the culture methods identified the predominant populations as determined 
by molecular testing, but in the majority of the samples, culture underreported the diversity of the 
wound microbiota and failed to detect the most abundant bacteria in the wound. Previous studies have 
demonstrated that using the molecular identification of bacteria to guide the management of chronic 
wounds can improve patient outcomes. 
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